医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Humacyte Selected to Join U.S. Secretary of Commerce On Trade Mission to Asia

2014年10月20日 PM10:00
このエントリーをはてなブックマークに追加


 

RESEARCH TRIANGLE PARK, N.C.

Humacyte, a pioneer in regenerative medicine, today announced it will join U.S. Secretary of Commerce Penny Pritzker on a Development Mission to Japan and South Korea later this month.

Humacyte bioengineers novel human tissue replacements that will be commercialized for key applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” human tissue replacements to pre-designed clinical and commercial specifications.

Humacyte will join 19 other regenerative medicine, pharmaceutical, and energy companies on the mission, which will make stops in Tokyo, Japan and Seoul, South Korea.

“We are grateful to the Department of Commerce and Secretary Pritzker for selecting Humacyte for such a unique opportunity for meaningful dialogue with influential Japanese and South Korean business executives, senior policy makers, academics, fellow innovators and peers leading health and technology within their markets,” said Dr. Ted Lithgow, chief operating officer, Humacyte. “Through this mission we hope to establish new relationships within these regions and with our mission partners. We see the delegation as an exciting way to enhance and expand the application of new technologies for patients in these regions who require vascular surgery. We look forward to sharing our story and our development insights to help progress the work of this community.”

The trade mission is focused on promoting U.S. business opportunities in the healthcare and energy sectors, to introduce the innovative companies to key decision-makers in government and business in Japan and South Korea. The delegation includes small companies with less than 100 employees as well as large multi-national firms that are interested in making inroads and tackling market access issues in Japan and South Korea.

The United States’ fourth and sixth-largest trading partners respectively, Japan and South Korea present ample opportunities for U.S. businesses. In both countries, the government and private sector are making significant investments in both health care and energy. Japan has a $153 billion market for medical and health products and South Korea’s total market for drugs and medical device products combined is approximately $21 billion.

About Humacyte

Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on bioengineering human tissue replacements for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. www.humacyte.com.

CONTACT

ICR
Matt Lindberg, 203-682-8214
matt.lindberg@icrinc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表